US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.
US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights:
- US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028
- US Cancer Antibodies Market To Witness More Than 200% Absolute Growth
- Current & Future market Projections by Drugs & Therapeutic Class
- Clinical Trials Insight On by Company, Indication, Patient Segment and Phase
- Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021
- Insight on FDA Approved 61 Cancer Antibodies Available in US Market
- Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market
- US Cancer Biosimilar Market Opportunity Insight
Download Report:
https://www.kuickresearch.com/report-us-cancer-antibodies-market
With the increasing prevalence of cancer cases in US, the demand for cancer therapies is also increasing. In recent times, the demand for targeted cancer therapies has gained sparked owing to their high specificity and enhanced efficiency over traditional cancer therapies. The entrance of therapeutic antibodies bring a forth in cancer immunotherapy by selectively targeting the antigens expressed on cancer cells. As of now, monoclonal antibodies as well as bispecific antibodies have entered the US market which has shown encouraging response in the management of several cancers. Apart from this, novel trispecific antibody construct has also been developed but is mainly confined to clinical development.
Among all approved therapeutic antibodies, immune checkpoint inhibitors are one of the most rapidly growing immunotherapeutic approaches and it is the leading segment of US cancer antibodies market. The safety and efficacy of immune checkpoint inhibitors is very high, which is mainly due to the unique mechanism of action of this category. At present, 8 immune checkpoint inhibitors have entered the US market while more than 300 trials related to the immune checkpoint inhibitors are under clinical investigation in US and most of the studies are in late stage of clinical trial. Some of the investigational immune checkpoint inhibitors are M7824, BMS-936559, and ASP8374 etc. Therefore, approval of new candidates is expected very soon, which will trigger the growth of this market segment in near future.
US is also home to several big pharmaceutical companies and the American consumers have access to one of the most advanced pharmaceutical systems in the world. The presence of large pharmaceutical sector increases competitions as well investments in research and development sector. Currently, about more than 1000 clinical trials are ongoing in US which are evaluating the role of novel therapeutic antibodies in the management of wide range of cancers including colorectal, ovarian, multiple myeloma, lymphoma, and other cancers. Apart from this, development of favorable reimbursement policies in the region also enhances the uptake of cancer antibodies in the region.
Recently, there has been shift in the approach of US pharmaceutical market. Both big pharmaceuticals and biotech companies have realized that these two sectors have more to gain from working together, than by competing. This has led to a flurry of deals being signed in the past few years between big pharma and big tech. For instance in 2021, Eisai and Bristol Myers Squibb announced that the companies have entered into an exclusive global strategic collaboration or the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRα) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker.
As per our analysis, the US cancer antibody market is expected to surpass US$ 80 Billion by 2028. A rapid increase in the number of smokers, coupled with a rise in sedentary lifestyles, has catalyzed the incidences of cancer cases in the region. On account of this, there has been acceleration in the demand for cost-effective and viable cancer treatments, including biosimilar oncology drugs. Apart from this, rising healthcare investments have resulted in the introduction of several improved and effective biosimilar oncology drugs, thereby positively influencing the market growth in the region. Furthermore, rising technological advancements in the healthcare sector have contributed to early cancer diagnosis, thus propelling the demand for antibodies in the market.
Our report provides comprehensive analysis on US FDA approved cancer antibodies therapeutics along with their commercial information including patent, price, dosage, and sales analysis. On the basis of drug type, the market is segmented into immune checkpoint inhibitors, monoclonal antibodies, bispecific antibodies, and antibody drug conjugates. Apart from this, the report also provides in-depth analysis on ongoing clinical trials in the market.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com